ADMA Biologics (ADMA) Stock Price, News & Analysis

Company Overview

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Key Stats

• Today's Range: $15.95 to $16.49
• 50-Day Range: $16.02 to $21.83
• 52-Week Range: $5.02 to $23.64
• Volume: 2.52 million shs
• Average Volume: 2.58 million shs
• Market Capitalization: $3.89 billion
• P/E Ratio: 58.82
• Dividend Yield: N/A
• Price Target: $21.25
• Consensus Rating: Buy

ADMA Biologics Stock Analysis - MarketRank™

ADMA Biologics scored higher than 83% of companies evaluated by MarketBeat, and ranked 186th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

ADMA Biologics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ADMA Biologics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 31.37%

Earnings Growth

Earnings for ADMA Biologics are expected to grow by 31.37% in the coming year, from $0.51 to $0.67 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ADMA Biologics is 58.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.57.

Price to Earnings Ratio vs. Sector

The P/E ratio of ADMA Biologics is 58.73, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 88.90.

Price to Book Value per Share Ratio

ADMA Biologics has a P/B Ratio of 27.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.76% of the outstanding shares of ADMA Biologics have been sold short.

Short Interest Ratio / Days to Cover

ADMA Biologics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ADMA Biologics has recently increased by 11.82%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ADMA Biologics does not currently pay a dividend.

Dividend Growth

ADMA Biologics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.76% of the outstanding shares of ADMA Biologics have been sold short.

Short Interest Ratio / Days to Cover

ADMA Biologics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ADMA Biologics has recently increased by 11.82%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.76

News Sentiment

ADMA Biologics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for ADMA Biologics this week, compared to 7 articles on an average week.

Search Interest

38 people have searched for ADMA on MarketBeat in the last 30 days. This is an increase of 15% compared to the previous 30 days.

MarketBeat Follows

Only 13 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -28% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ADMA Biologics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $317,250.00 in company stock.

Percentage Held by Insiders

Only 3.70% of the stock of ADMA Biologics is held by insiders.

Percentage Held by Institutions

75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ADMA Stock Analysis - Frequently Asked Questions

How have ADMA shares performed this year?

ADMA Biologics' stock was trading at $17.15 at the beginning of the year. Since then, ADMA shares have decreased by 4.2% and is now trading at $16.4360.
View the best growth stocks for 2025 here.

How were ADMA Biologics' earnings last quarter?

ADMA Biologics, Inc. (NASDAQ:ADMA) issued its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.13 by $0.02. The biotechnology company had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a net margin of 17.80% and a trailing twelve-month return on equity of 53.20%.

Who are ADMA Biologics' major shareholders?

Top institutional shareholders of ADMA Biologics include Perpetual Ltd (1.54%), Assenagon Asset Management S.A. (0.25%), Janney Montgomery Scott LLC (0.03%) and Veracity Capital LLC (0.02%). Insiders that own company stock include Steve Elms, Adam S Grossman, Brian Lenz, Jerrold B Grossman, Kaitlin M Kestenberg-Messina, Young Kwon, Brad L Tade, Lawrence P Guiheen and Bryant Fong.
View institutional ownership trends.

How do I buy shares of ADMA Biologics?

Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ADMA Biologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ADMA Biologics investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 1/22/2025
• Next Earnings (Estimated): 2/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADMA
• CUSIP: N/A
• CIK: 1368514
• Web: www.admabiologics.com
• Phone: (201) 478-5552
• Fax: 201-478-5553
• Employees: 530
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.25
• High Stock Price Target: $26.00
• Low Stock Price Target: $14.00
• Potential Upside/Downside: +31.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.28
• Trailing P/E Ratio: 57.39
• Forward P/E Ratio: 31.61
• P/E Growth: N/A
• Net Income: $-28,240,000.00
• Net Margins: 17.80%
• Pretax Margin: 19.16%
• Return on Equity: 53.20%
• Return on Assets: 26.07%

Debt

• Debt-to-Equity Ratio: 0.48
• Current Ratio: 7.09
• Quick Ratio: 3.26

Sales & Book Value

• Annual Sales: $258.21 million
• Price / Sales: 14.76
• Cash Flow: $0.05 per share
• Price / Cash Flow: 315.24
• Book Value: $0.60 per share
• Price / Book: 26.87

Miscellaneous

• Outstanding Shares: 236,390,000
• Free Float: 227,644,000
• Market Cap: $3.81 billion
• Optionable: Optionable
• Beta: 0.76